CURATIS N AG

SW:CURN Switzerland Drug Manufacturers - Specialty & Generic
Market Cap
$134.46 Million
CHF123.13 Million CHF
Market Cap Rank
#38786 Global
#134 in Switzerland
Share Price
CHF23.90
Change (1 day)
+0.00%
52-Week Range
CHF9.72 - CHF26.00
All Time High
CHF891.52
Categories
Companies in Switzerland Drug Manufacturers - Specialty & Generic
About

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antih… Read more

CURATIS N AG (CURN) - Net Assets

Latest net assets as of June 2025: CHF44.56 Million CHF

Based on the latest financial reports, CURATIS N AG (CURN) has net assets worth CHF44.56 Million CHF as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF54.52 Million) and total liabilities (CHF9.96 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CHF44.56 Million
% of Total Assets 81.73%
Annual Growth Rate -0.88%
5-Year Change N/A
10-Year Change 630.74%
Growth Volatility 175.51

CURATIS N AG - Net Assets Trend (2002–2024)

This chart illustrates how CURATIS N AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for CURATIS N AG (2002–2024)

The table below shows the annual net assets of CURATIS N AG from 2002 to 2024.

Year Net Assets Change
2024-12-31 CHF45.60 Million +14714.74%
2023-12-31 CHF-312.00K -104.62%
2022-12-31 CHF6.75 Million +1788.25%
2021-12-31 CHF-400.00K -55.64%
2020-12-31 CHF-257.00K +53.44%
2019-12-31 CHF-552.00K -246.42%
2018-12-31 CHF377.00K -91.94%
2017-12-31 CHF4.68 Million -7.18%
2016-12-31 CHF5.04 Million -19.21%
2015-12-31 CHF6.24 Million -20.99%
2014-12-31 CHF7.90 Million -9.29%
2013-12-31 CHF8.71 Million -24.97%
2012-12-31 CHF11.60 Million +62.09%
2011-12-31 CHF7.16 Million +2.58%
2010-12-31 CHF6.98 Million +18.63%
2009-12-31 CHF5.88 Million +258.06%
2008-12-31 CHF1.64 Million +623.79%
2007-12-31 CHF227.00K -97.56%
2006-12-31 CHF9.30 Million -57.10%
2005-12-31 CHF21.67 Million -41.89%
2004-12-31 CHF37.30 Million -25.15%
2003-12-31 CHF49.83 Million -9.94%
2002-12-31 CHF55.33 Million --

Equity Component Analysis

This analysis shows how different components contribute to CURATIS N AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 148600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock CHF484.00K 1.06%
Other Components CHF72.11 Million 158.14%
Total Equity CHF45.60 Million 100.00%

CURATIS N AG Competitors by Market Cap

The table below lists competitors of CURATIS N AG ranked by their market capitalization.

Company Market Cap
VEECO INSTRUMENTS - Dusseldorf Stock Exchang
DU:VEO
 		$259.22K
Wildpack Beverage Inc
PINK:WLDPF
 		$259.25K
Plastofil -L
TA:PPIL
 		$259.26K
OEKOWORLD AG
STU:VVV3
 		$259.49K
NEWPATH RESOURCES INC.
F:0MZ
 		$258.92K
Grayscale Stellar Lumens Trust XlM
OTCQX:GXLM
 		$258.75K
GAS NATURAL SDG
BE:GAN
 		$258.58K
Prima Moda SA
WAR:PMA
 		$258.58K

Equity Growth Attribution

This analysis shows how different factors contributed to changes in CURATIS N AG's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from -312,000 to 45,598,000, a change of 45,910,000.
  • Net loss of 4,345,000 reduced equity.
  • Share repurchases of 14,000 reduced equity.
  • Other factors increased equity by 50,269,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CHF-4.34 Million -9.53%
Share Repurchases CHF14.00K -0.03%
Other Changes CHF50.27 Million +110.24%
Total Change CHF- %

Book Value vs Market Value Analysis

This analysis compares CURATIS N AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.53x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 2.78x to 1.53x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2002-12-31 CHF8.59 CHF23.90 x
2003-12-31 CHF6.23 CHF23.90 x
2004-12-31 CHF4.66 CHF23.90 x
2005-12-31 CHF2.68 CHF23.90 x
2006-12-31 CHF1.02 CHF23.90 x
2007-12-31 CHF0.02 CHF23.90 x
2008-12-31 CHF0.04 CHF23.90 x
2009-12-31 CHF0.04 CHF23.90 x
2010-12-31 CHF0.05 CHF23.90 x
2011-12-31 CHF0.05 CHF23.90 x
2012-12-31 CHF0.07 CHF23.90 x
2013-12-31 CHF0.05 CHF23.90 x
2014-12-31 CHF0.04 CHF23.90 x
2015-12-31 CHF0.03 CHF23.90 x
2016-12-31 CHF0.03 CHF23.90 x
2017-12-31 CHF0.03 CHF23.90 x
2018-12-31 CHF0.00 CHF23.90 x
2019-12-31 CHF0.00 CHF23.90 x
2020-12-31 CHF0.00 CHF23.90 x
2021-12-31 CHF0.00 CHF23.90 x
2022-12-31 CHF43.09 CHF23.90 x
2023-12-31 CHF-1.11 CHF23.90 x
2024-12-31 CHF15.67 CHF23.90 x

Capital Efficiency Dashboard

This dashboard shows how efficiently CURATIS N AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -9.53%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -63.01%
  • • Asset Turnover: 0.12x
  • • Equity Multiplier: 1.22x
  • Recent ROE (-9.53%) is above the historical average (-256.44%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2002 -27.15% -136.80% 0.16x 1.25x CHF-20.56 Million
2003 -13.95% -15.27% 0.64x 1.43x CHF-11.94 Million
2004 -35.13% -42.99% 0.51x 1.60x CHF-16.83 Million
2005 -96.93% -118.60% 0.51x 1.60x CHF-23.18 Million
2006 -138.60% -75.79% 1.22x 1.50x CHF-13.82 Million
2007 -4363.88% -189.66% 0.56x 41.24x CHF-9.93 Million
2008 -462.26% -476.47% 0.31x 3.10x CHF-7.76 Million
2009 20.31% 11.84% 1.22x 1.41x CHF606.70K
2010 15.93% 4.11% 2.02x 1.91x CHF414.10K
2011 2.82% 0.93% 1.77x 1.71x CHF-513.90K
2012 -3.47% -1.15% 1.82x 1.66x CHF-1.56 Million
2013 -7.47% -2.37% 2.35x 1.34x CHF-1.52 Million
2014 -10.40% -3.37% 2.45x 1.26x CHF-1.61 Million
2015 -26.19% -10.48% 1.96x 1.28x CHF-2.26 Million
2016 -20.15% -5.66% 2.53x 1.41x CHF-1.52 Million
2017 -5.56% -1.48% 2.63x 1.43x CHF-727.90K
2018 -202.12% -4.71% 7.39x 5.81x CHF-799.70K
2019 0.00% -5.43% 7.96x 0.00x CHF-884.80K
2020 0.00% -0.39% 32.35x 0.00x CHF9.70K
2021 0.00% 0.00% 0.00x 0.00x CHF177.00K
2022 -514.32% 0.00% 0.00x 2.08x CHF-35.41 Million
2023 0.00% 0.00% 0.00x 0.00x CHF-49.35 Million
2024 -9.53% -63.01% 0.12x 1.22x CHF-8.90 Million

Industry Comparison

This section compares CURATIS N AG's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $359,838,500
  • Average return on equity (ROE) among peers: 4.69%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
CURATIS N AG (CURN) CHF44.56 Million -27.15% 0.22x $259.11K
PolyPeptide Group AG (PPGN) $357.24 Million -5.48% 1.12x $345.17 Million
Siegfried Holding Ltd (SFZN) $362.43 Million 14.86% 0.48x $3.38 Billion